Hendriks, H R <br/><br/>
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  1993 
 - 897-906 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0959-8049 
<br/><br/><label>Standard No.: </label>10.1016/s0959-8049(05)80434-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Animals<br/>Antineoplastic Agents--therapeutic use<br/>Aziridines--therapeutic use<br/>Bone Marrow--drug effects<br/>Cell Survival--drug effects<br/>Colonic Neoplasms--drug therapy<br/>Dose-Response Relationship, Drug<br/>Drug Evaluation, Preclinical<br/>Female<br/>Humans<br/>Indolequinones<br/>Indoles--therapeutic use<br/>Leukemia P388--drug therapy<br/>Male<br/>Mice<br/>Neoplasm Transplantation<br/>Rats<br/>Tumor Cells, Cultured--drug effects